FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207768> ?p ?o ?g. }

• W4387207768 endingPage "e335" @default.
• W4387207768 startingPage "e335" @default.
• W4387207768 abstract "For patients with oligometastatic colorectal cancer (CRC), aggressive local therapy of isolated metastases, particularly in the liver, has been associated with long-term progression-free survival and overall survival (OS) primarily based on retrospective evidence. However, in patients with limited metastatic CRC that is deemed inoperable or those with additional disease outside of the liver or lungs, the role of local ablative therapies, including microwave ablation (MWA) and stereotactic body radiation therapy (SBRT), to render patients disease free is less clear. Further, despite the long history of treating oligometastatic CRC with local therapy, which is provider biased and not evidence based, questions remain regarding the benefit of extending the paradigm of metastatic directed therapy to patients with more extensive disease. This trial seeks to use a pragmatic multimodality approach that mirrors the current clinical dilemma. This study is designed to evaluate the safety and efficacy of adding total ablative therapy (TAT) of all sites of disease to standard of care systemic treatment in those with limited metastatic CRC.A022101 is a National Clinical Trials Network randomized phase III study planned to enroll 364 patients with newly diagnosed metastatic CRC (BRAF wild-type, microsatellite stable) with 4 or fewer sites of metastatic disease on baseline imaging. Liver-only metastatic disease is not permitted, and lesions must be amenable to any combination of surgical resection, MWA, and/or SBRT with SBRT required for at least one lesion. Patients receive first-line systemic therapy for 4-6 months and are then randomized 1:1, stratified by number of metastatic organ sites (1-2 vs. 3-4), timing of metastatic disease diagnosis (de novo vs. secondary), and presence of metastatic disease outside the liver and lungs in at least one site. Patients in Arm 1 will receive TAT which consists of treatment of all metastatic sites with SBRT ± MWA ± surgical resection followed by standard of care systemic therapy. Patients in Arm 2 will continue with standard of care systemic therapy alone. The primary endpoint is OS. Secondary endpoints include event-free survival, treatment-related toxicities, and local recurrence with exploratory biomarker analyses. The study needs 346 evaluable patients combined in the 2 arms to demonstrate an improvement in OS with a hazard ratio of 0.7 to provide 80% power with a one-sided alpha of 5%. The trial utilizes a group sequential design with two interim analyses (25% and 50% of events) for futility.The trial activated in January 2023.Recruitment is ongoing." @default.
• W4387207768 created "2023-09-30" @default.
• W4387207768 creator A5020154592 @default.
• W4387207768 creator A5027170448 @default.
• W4387207768 creator A5028462034 @default.
• W4387207768 creator A5031343159 @default.
• W4387207768 creator A5036695687 @default.
• W4387207768 creator A5038339239 @default.
• W4387207768 creator A5043067705 @default.
• W4387207768 creator A5044225007 @default.
• W4387207768 creator A5049291606 @default.
• W4387207768 creator A5054605021 @default.
• W4387207768 creator A5066218667 @default.
• W4387207768 creator A5071197533 @default.
• W4387207768 creator A5077769345 @default.
• W4387207768 creator A5079795657 @default.
• W4387207768 creator A5080751418 @default.
• W4387207768 creator A5085027120 @default.
• W4387207768 creator A5085239564 @default.
• W4387207768 date "2023-10-01" @default.
• W4387207768 modified "2023-10-17" @default.
• W4387207768 title "Alliance A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer – Evaluating Radiation, Ablation and Surgery (ERASur)" @default.
• W4387207768 doi "https://doi.org/10.1016/j.ijrobp.2023.06.2391" @default.
• W4387207768 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785178" @default.
• W4387207768 hasPublicationYear "2023" @default.
• W4387207768 type Work @default.
• W4387207768 citedByCount "0" @default.
• W4387207768 crossrefType "journal-article" @default.
• W4387207768 hasAuthorship W4387207768A5020154592 @default.
• W4387207768 hasAuthorship W4387207768A5027170448 @default.
• W4387207768 hasAuthorship W4387207768A5028462034 @default.
• W4387207768 hasAuthorship W4387207768A5031343159 @default.
• W4387207768 hasAuthorship W4387207768A5036695687 @default.
• W4387207768 hasAuthorship W4387207768A5038339239 @default.
• W4387207768 hasAuthorship W4387207768A5043067705 @default.
• W4387207768 hasAuthorship W4387207768A5044225007 @default.
• W4387207768 hasAuthorship W4387207768A5049291606 @default.
• W4387207768 hasAuthorship W4387207768A5054605021 @default.
• W4387207768 hasAuthorship W4387207768A5066218667 @default.
• W4387207768 hasAuthorship W4387207768A5071197533 @default.
• W4387207768 hasAuthorship W4387207768A5077769345 @default.
• W4387207768 hasAuthorship W4387207768A5079795657 @default.
• W4387207768 hasAuthorship W4387207768A5080751418 @default.
• W4387207768 hasAuthorship W4387207768A5085027120 @default.
• W4387207768 hasAuthorship W4387207768A5085239564 @default.
• W4387207768 hasConcept C121608353 @default.
• W4387207768 hasConcept C126322002 @default.
• W4387207768 hasConcept C126838900 @default.
• W4387207768 hasConcept C141071460 @default.
• W4387207768 hasConcept C143998085 @default.
• W4387207768 hasConcept C168563851 @default.
• W4387207768 hasConcept C185926286 @default.
• W4387207768 hasConcept C2777377203 @default.
• W4387207768 hasConcept C2778902805 @default.
• W4387207768 hasConcept C2780387249 @default.
• W4387207768 hasConcept C509974204 @default.
• W4387207768 hasConcept C526805850 @default.
• W4387207768 hasConcept C530470458 @default.
• W4387207768 hasConcept C535046627 @default.
• W4387207768 hasConcept C71924100 @default.
• W4387207768 hasConceptScore W4387207768C121608353 @default.
• W4387207768 hasConceptScore W4387207768C126322002 @default.
• W4387207768 hasConceptScore W4387207768C126838900 @default.
• W4387207768 hasConceptScore W4387207768C141071460 @default.
• W4387207768 hasConceptScore W4387207768C143998085 @default.
• W4387207768 hasConceptScore W4387207768C168563851 @default.
• W4387207768 hasConceptScore W4387207768C185926286 @default.
• W4387207768 hasConceptScore W4387207768C2777377203 @default.
• W4387207768 hasConceptScore W4387207768C2778902805 @default.
• W4387207768 hasConceptScore W4387207768C2780387249 @default.
• W4387207768 hasConceptScore W4387207768C509974204 @default.
• W4387207768 hasConceptScore W4387207768C526805850 @default.
• W4387207768 hasConceptScore W4387207768C530470458 @default.
• W4387207768 hasConceptScore W4387207768C535046627 @default.
• W4387207768 hasConceptScore W4387207768C71924100 @default.
• W4387207768 hasIssue "2" @default.
• W4387207768 hasLocation W43872077681 @default.
• W4387207768 hasLocation W43872077682 @default.
• W4387207768 hasOpenAccess W4387207768 @default.
• W4387207768 hasPrimaryLocation W43872077681 @default.
• W4387207768 hasRelatedWork W1481696870 @default.
• W4387207768 hasRelatedWork W2003938723 @default.
• W4387207768 hasRelatedWork W2032855511 @default.
• W4387207768 hasRelatedWork W2047967234 @default.
• W4387207768 hasRelatedWork W2118496982 @default.
• W4387207768 hasRelatedWork W2439875401 @default.
• W4387207768 hasRelatedWork W2757781531 @default.
• W4387207768 hasRelatedWork W2891298884 @default.
• W4387207768 hasRelatedWork W3208803946 @default.
• W4387207768 hasRelatedWork W2525756941 @default.
• W4387207768 hasVolume "117" @default.
• W4387207768 isParatext "false" @default.
• W4387207768 isRetracted "false" @default.
• W4387207768 workType "article" @default.